Article
[Experience with the use of gefitinib in patients with inoperable non-squamous cell lung cancer with activating EGFR mutations].
Voprosy onkologii - 1 Jan 2015
Moiseenko V M, Chubenko V A, Moiseenko F V, Ivantsov A O, Kramchaninov M M, Imyanitov E N
Abstract excerpt
Discovery of activating EGFR mutations led to dramatic modification of treatment schemes for nonsquamous lung cancer. 70 patients with activating EGFR mutations were treated by gefitinib being either a part of prospective phase II trial (n = 25) or, subsequently, subjected to routine clinical management (n = 45). Objective response rate approached to 32.7%. Median time to disease progression was 14 months, and...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Disease-Free Survival
- ErbB Receptors
- Female
- Gefitinib
- Humans
- Lung Neoplasms
- Male
- Middle Aged
- Mutation
- Prospective Studies
- Protein Kinase Inhibitors
- Quinazolines
- Survival Analysis